Protara Therapeutics, Inc.

Protara Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing transformative therapies for individuals battling cancer and rare diseases. Headquartered in New York, NY, the company focuses on addressing significant unmet medical needs through its innovative pipeline.

The company's primary product candidates include TARA-002 and intravenous (IV) Choline Chloride. TARA-002 is an investigational cell-based therapy currently in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). IV Choline Chloride is an investigational phospholipid substrate replacement therapy aimed at patients dependent on parenteral support who are unable to meet their choline requirements through oral or enteral routes.

Recent developments for Protara Therapeutics include positive updated 12-month data from its Phase 2 ADVANCED-2 trial of TARA-002 in BCG-Naïve NMIBC patients. TARA-002 has also received Rare Pediatric Disease, Breakthrough Therapy, and Fast Track designations from the U.S. FDA for lymphatic malformations. The company's leadership team includes Jesse Shefferman as President and CEO, and it anticipates its current cash and investments will fund planned operations into 2028.